Strides Pharma Science Limited — Investor Meet, 03-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Strides Pharma reported its highest ever quarterly EBITDA of Rs 236 Cr, up 12% YoY with a 19.8% margin. 9M operational PAT grew 65% to Rs 382 Cr, surpassing full FY25 PAT. Gross margins touched 59.8%. Ex-US markets contributed 47% of Q3 revenue, growing 20% YoY to $64 million, with ORM at $48 million. US revenue remained at $70 million, impacted by muted flu season, competition, and product discontinuations. Management reaffirms its $400 million US revenue target by FY28, backed by dormant product relaunches, control substances, and R&D. Debt/EBITDA improved to 1.59x. The company emphasizes geographical diversification and balance sheet strength as core priorities.